• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Politan Nominates Two Candidates for Masimo Board

    5/2/23 7:00:00 AM ET
    $BG
    $CAH
    $CNC
    $LOW
    Packaged Foods
    Consumer Staples
    Other Pharmaceuticals
    Health Care
    Get the next $BG alert in real time by email

    Nominees Michelle Brennan and Quentin Koffey Bring Relevant Industry Experience, a Focus on Profitable Growth and Shareholder Alignment to a Board in Need of Independent Oversight

    Visit www.AdvanceMasimo.com for Additional Information

    Politan Capital Management (together with its affiliates, "Politan"), a 9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today announced that it has nominated two candidates for election to the Masimo Board of Directors (the "Board") at the upcoming 2023 Annual Meeting of Stockholders (the "Annual Meeting"), which is currently scheduled for June 26, 2023.

    Politan's nominees are:

    • Michelle Brennan, a former senior executive at Johnson & Johnson ("J&J") for more than 30 years, where she oversaw medical device businesses globally as well as consumer pharmaceutical businesses. At J&J, Michelle successfully scaled multiple businesses from inception to several billion in revenue and led efforts to invest in innovation that resulted in successful new product launches. Michelle is currently an independent director at Cardinal Health (NYSE:CAH) and recently served on the Board of Coupa Software (NASDAQ:COUP). If elected to the Masimo Board, Michelle would bring decades of successful experience reinvigorating profitable growth in the healthcare sector.



    • Quentin Koffey, Managing Partner and Chief Investment Officer of Politan. Quentin has an established track record of working constructively with boards and management teams to enhance shareholder value, including at companies such as Centene (NYSE:CNC), Lowe's Companies (NYSE:LOW), Louisiana-Pacific (NYSE:LPX), Bunge (NYSE:BG), and Marathon Petroleum (NYSE:MPC). If elected to the Masimo Board, Quentin would bring a shareholder perspective as one of the Company's largest owners, in addition to highly relevant corporate governance, capital allocation and finance experience.

    Mr. Koffey stated:

    "As a 9% owner of Masimo, Politan is fully aligned with the success of the Company and its ability to generate long-term value. We believe independent oversight is needed on the Board in order to fix the lack of confidence in Masimo's governance that has led to a persistent valuation discount of over $4 billion. This is why Politan has nominated two ideally qualified director candidates for election at the 2023 Annual Meeting who are committed to representing the interests of all shareholders.

    Over the past eight months, we have attempted to engage constructively with Masimo's Board – but they have refused to even meet with us. Despite our track record of working privately with companies to fix strategic, operational and governance matters, Masimo's Board has taken an extraordinarily aggressive and hostile approach to our engagement. The Board has enacted widely criticized and illegal bylaws, attempted to use litigation to force Politan to disclose commercially sensitive information and tried to contact and pressure Politan's own investors. These actions are consistent with Masimo's history of disregard for shareholders and further evidence of the need for change. Following the Company's March 23rd announcement that it would adopt some long overdue governance changes, we again attempted to work constructively with the Company, only to find the same utter lack of interest in engagement.

    Together, Michelle and I would bring a unique set of needed skills to the Masimo Board. She has deep expertise from decades spent in relevant roles at one of the most respected healthcare and consumer products companies in the world, in addition to experience as a public company director. I would add a true independent ownership perspective and my experience from dozens of collaborative engagements focused on improving capital allocation and corporate governance at companies across sectors. We both believe in the future of Masimo and that it has the opportunity for tremendous ongoing success. By electing us, shareholders will be adding to the Board independent, objective directors with the right skills and experience to help the Company maximize its potential for all its stakeholders.

    We look forward to engaging with our fellow shareholders in the near future."

    For additional information, shareholders can visit www.AdvanceMasimo.com.

    Full Biographies of Politan's Nominees

    Michelle Brennan is an accomplished healthcare executive with over 30 years of experience at Johnson & Johnson. Michelle most recently served as Global Value Creation Leader and a member of the Medical Device Executive Leadership Team. Prior to this, she held a variety of roles, including Company Group Chair of J&J's Medical Device business in Europe, Middle East & Africa. Over her tenure, Michelle had P&L responsibility for a more than $5 billion medical device business operating across diverse business models and geographies. She also successfully scaled multiple businesses from inception to several billion in revenue and led efforts to invest in innovation as well as optimize the R&D process, which resulted in more effective and profitable product launches and more efficient spend. Michelle has broad operational experience across medical devices and consumer pharmaceuticals and is known for her expertise in strategy implementation, new product innovation, and business transformation.

    Michelle is currently an independent director at Cardinal Health (NYSE:CAH) and is a member of the Audit and Human Resources & Compensation Committees. She recently served on the Board of Coupa Software (NASDAQ:COUP) as an independent director, where she was Chair of the Nominating and Corporate Governance Committee and a member of the Audit Committee, until the completion of Coupa's acquisition by Thoma Bravo for $8 billion in February of 2023. Michelle holds a BA from the University of Kansas and has attended Executive MBA courses at the Wharton School of the University of Pennsylvania.

    Quentin Koffey is the Managing Partner and Chief Investment Officer of Politan Capital, a top shareholder of Masimo Corporation. In this role, Quentin leads efforts to work actively with management teams, boards of directors, and shareholders of portfolio companies on strategic, operational, and corporate governance matters to unlock long-term value for shareholders. Prior to founding Politan, Quentin was a partner at Senator Investment Group LP, where he created and led its shareholder engagement efforts, and a Portfolio Manager for Strategic Investments at The D.E. Shaw Group, where he started and led the firm's shareholder engagement strategy. Quentin also served as a Portfolio Manager at Elliott Management Corporation where he focused on active investments in public and private equity and credit.

    Over his career, Quentin has established a track record of working constructively with boards and management teams to enhance shareholder value, including at companies such as Centene (NYSE:CNC), Lowe's Companies (NYSE:LOW), Louisiana-Pacific (NYSE:LPX), Bunge (NYSE:BG), and Marathon Petroleum (NYSE:MPC). Quentin holds a BA from Yale College, a JD from Stanford Law School, and an MBA from Stanford Graduate School of Business.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein in any state to any person. The information herein contains "forward-looking statements." Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "potential," "targets," "forecasts," "seeks," "could," "should" or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if Politan's underlying assumptions prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward-looking statements should not be regarded as a representation by Politan that the future plans, estimates or expectations contemplated will ever be achieved.

    Certain Information Concerning the Participants

    Politan Capital Management LP ("Politan Capital") and the other Participants (as defined below) will file a preliminary proxy statement and accompanying BLUE universal proxy card with the Securities and Exchange Commission (the "SEC") on May 2, 2023 to be used to solicit proxies for, among other matters, the election of its slate of director nominees at the Annual Meeting. Promptly after filing its definitive proxy statement with the SEC, Politan Capital will mail the definitive proxy statement and accompanying BLUE universal proxy card to each stockholder entitled to vote at the 2023 Annual Meeting.

    The participants in the proxy solicitation are Politan Capital, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, Politan Capital NY LLC, Politan Intermediate Ltd., Politan Capital Partners Master Fund LP ("Politan Master Fund"), Politan Capital Partners LP ("Politan LP"), Politan Capital Offshore Partners LP ("Politan Offshore" and collectively with Politan Master Fund and Politan LP, the "Politan Funds"), Quentin Koffey, Matthew Hall, Aaron Kapito and Michelle Brennan (collectively, the "Participants").

    As of the date hereof, (i) Politan Master Fund directly owns 4,712,518 shares of common stock, par value $0.001 per share, of Masimo (the "Common Stock"), and (ii) Politan Capital NY LLC is the direct and record owner of 1,000 shares of Common Stock.

    Politan Capital, as the investment adviser to the Politan Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) 4,713,518 shares of Common Stock (the "Politan Shares") and, therefore, Politan Capital may be deemed to be the beneficial owner of all of the Politan Shares. The Politan Shares collectively represent approximately 9.0% of the outstanding shares of Common Stock based on 52,601,943 shares of Common Stock outstanding as of January 28, 2023, as reported in Masimo's Annual Report on Form 10-K filed on March 1, 2023. As the general partner of Politan Capital, Politan Capital Management GP LLC may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Politan Shares and, therefore, Politan Capital Management GP LLC may be deemed to be the beneficial owner of all of the Politan Shares. As the general partner of the Politan Funds, Politan Capital Partners GP LLC may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) all of the Politan Shares and, therefore, Politan Capital Partners GP LLC may be deemed to be the beneficial owner of all of the Politan Shares. By virtue of Mr. Koffey's position as the managing partner and chief investment officer of Politan and as the managing member of Politan Capital Management GP LLC and Politan Capital Partners GP LLC, Mr. Koffey may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Politan Shares and, therefore, Mr. Koffey may be deemed to be the beneficial owner of all of the Politan Shares. As of the date hereof, none of Mr. Hall, Mr. Kapito or Ms. Brennan own beneficially or of record any shares of Common Stock.

    Important Information and Where to Find It

    POLITAN CAPITAL STRONGLY ADVISES ALL STOCKHOLDERS OF MASIMO TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT WWW.SEC.GOV. THE DEFINITIVE PROXY STATEMENT, WHEN FILED, AND OTHER RELEVANT DOCUMENTS, WILL ALSO BE AVAILABLE ON WWW.ADVANCEMASIMO.COM AND THE SEC WEBSITE, FREE OF CHARGE, OR BY DIRECTING A REQUEST TO THE PARTICIPANTS' PROXY SOLICITOR, D.F. KING & CO., INC., 48 WALL STREET, 22ND FLOOR, NEW YORK, NEW YORK 10005 (STOCKHOLDERS CAN CALL TOLL-FREE: +1 (866) 620-9554).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005565/en/

    Get the next $BG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BG
    $CAH
    $CNC
    $LOW

    CompanyDatePrice TargetRatingAnalyst
    Centene Corporation
    $CNC
    7/23/2025$30.00Overweight → Equal Weight
    Wells Fargo
    Centene Corporation
    $CNC
    7/21/2025$33.00Buy → Hold
    TD Cowen
    Centene Corporation
    $CNC
    7/16/2025$30.00Neutral → Underperform
    BofA Securities
    Marathon Petroleum Corporation
    $MPC
    7/15/2025$200.00Strong Buy → Outperform
    Raymond James
    Marathon Petroleum Corporation
    $MPC
    7/14/2025Outperform → Peer Perform
    Wolfe Research
    Centene Corporation
    $CNC
    7/10/2025$33.00Overweight → Equal-Weight
    Morgan Stanley
    Centene Corporation
    $CNC
    7/2/2025$45.00Buy → Neutral
    UBS
    Centene Corporation
    $CNC
    7/2/2025$48.00Overweight → Neutral
    Analyst
    More analyst ratings

    $BG
    $CAH
    $CNC
    $LOW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Hessling Ricky D. bought $269,440 worth of shares (2,000 units at $134.72), increasing direct ownership by 20% to 12,162 units (SEC Form 4)

      4 - Marathon Petroleum Corp (0001510295) (Issuer)

      3/13/25 6:55:55 AM ET
      $MPC
      Integrated oil Companies
      Energy
    • Director Bayh Evan bought $133,700 worth of shares (1,000 units at $133.70), increasing direct ownership by 1% to 69,305 units (SEC Form 4)

      4 - Marathon Petroleum Corp (0001510295) (Issuer)

      3/7/25 7:10:39 AM ET
      $MPC
      Integrated oil Companies
      Energy
    • Director Simkins Lawrence bought $245,532 worth of shares (1,000 units at $245.53) (SEC Form 4)

      4 - LOWES COMPANIES INC (0000060667) (Issuer)

      12/23/24 4:10:11 PM ET
      $LOW
      RETAIL: Building Materials
      Consumer Discretionary

    $BG
    $CAH
    $CNC
    $LOW
    SEC Filings

    See more
    • SEC Form 10-Q filed by Centene Corporation

      10-Q - CENTENE CORP (0001071739) (Filer)

      7/24/25 9:45:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CENTENE CORP (0001071739) (Filer)

      7/24/25 9:46:22 PM ET
      $CNC
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Bunge Limited

      EFFECT - Bunge Global SA (0001996862) (Filer)

      7/21/25 12:15:19 AM ET
      $BG
      Packaged Foods
      Consumer Staples

    $BG
    $CAH
    $CNC
    $LOW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CENTENE CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

      -- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) -- ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows: Total revenues (in millions) $             48,742 Premium and service revenues (in millions) $             42,467 Health benefits ratio 93.0 % SG&A expense ratio 7.1 % Adjusted SG&A expense ratio (1) 7.1 % GAAP diluted loss per share $                (0.51) Adjusted diluted loss per share (1) $                (0.16) Total cash flow provided by operations (in millions) $              

      7/25/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • NIRI Chicago Elects 2025-2026 Officers and Directors

      The Chicago chapter of NIRI, The Association for Investor Relations (NIRI Chicago), has elected 12 officers and directors to its board for the 2025-2026 term, effective July 1. "This has been an uncertain time for investor relations officers and consultants as they navigate the implications of economic change, stock market volatility and breaking news," said Rob Cherry, incoming chapter president. "Our new board will work hard to ensure strong professional development and networking opportunities to help our members stay on top of trends and effectively represent their companies and clients to institutional investors and other stakeholders. As part of that mission, we look forward to welc

      7/22/25 3:53:00 PM ET
      $ALL
      $BLDR
      $BMI
      $BY
      Property-Casualty Insurers
      Finance
      RETAIL: Building Materials
      Consumer Discretionary
    • Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

      Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered partic

      7/22/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BG
    $CAH
    $CNC
    $LOW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Co-Chief Operating Officer Mattiske David was granted 95,017 shares, increasing direct ownership by 168% to 151,486 units (SEC Form 4)

      4 - Bunge Global SA (0001996862) (Issuer)

      7/17/25 4:52:03 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • New insider Canada Pension Plan Investment Board claimed ownership of 26,244,732 units of Registered Shares (SEC Form 3)

      3 - Bunge Global SA (0001996862) (Issuer)

      7/8/25 5:48:07 PM ET
      $BG
      Packaged Foods
      Consumer Staples
    • Director Jensen Anne was granted 2,164 shares (SEC Form 4)

      4 - Bunge Global SA (0001996862) (Issuer)

      7/7/25 7:03:37 PM ET
      $BG
      Packaged Foods
      Consumer Staples

    $BG
    $CAH
    $CNC
    $LOW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Centene downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Centene from Overweight to Equal Weight and set a new price target of $30.00

      7/23/25 7:38:36 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene downgraded by TD Cowen with a new price target

      TD Cowen downgraded Centene from Buy to Hold and set a new price target of $33.00

      7/21/25 8:26:59 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene downgraded by BofA Securities with a new price target

      BofA Securities downgraded Centene from Neutral to Underperform and set a new price target of $30.00

      7/16/25 7:52:45 AM ET
      $CNC
      Medical Specialities
      Health Care

    $BG
    $CAH
    $CNC
    $LOW
    Leadership Updates

    Live Leadership Updates

    See more
    • Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

      American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

      7/8/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Shareholders Elect Four Independent Directors to the Six Flags Board

      Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St

      6/25/25 5:00:00 PM ET
      $BUD
      $CBRL
      $DG
      $FUN
      Beverages (Production/Distribution)
      Consumer Staples
      Restaurants
      Consumer Discretionary
    • LP Building Solutions Names Tony Hamill as Chief Operating Officer

      LP Building Solutions (LP), a leading manufacturer of high-performance building products, today announced the appointment of Tony Hamill as Senior Vice President, Chief Operating Officer, effective June 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619923354/en/LP Building Solutions Chief Operating Officer Tony Hamill "As we execute our long-term growth strategy, I am pleased to appoint Tony to the newly created role of Chief Operating Officer," said LP President Jason Ringblom. "With over 30 years of leadership experience in engineering and manufacturing—much of it within our own organization—Tony brings comprehen

      6/19/25 9:00:00 AM ET
      $LPX
      Forest Products
      Basic Materials

    $BG
    $CAH
    $CNC
    $LOW
    Financials

    Live finance-specific insights

    See more
    • CENTENE CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

      -- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) -- ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows: Total revenues (in millions) $             48,742 Premium and service revenues (in millions) $             42,467 Health benefits ratio 93.0 % SG&A expense ratio 7.1 % Adjusted SG&A expense ratio (1) 7.1 % GAAP diluted loss per share $                (0.51) Adjusted diluted loss per share (1) $                (0.16) Total cash flow provided by operations (in millions) $              

      7/25/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

      Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered partic

      7/22/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CENTENE CORPORATION TO HOST 2025 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL

      CALL MOVED TO 8AM ET ST. LOUIS, July 22, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 second quarter financial results at approximately 6:00 a.m. ET on Friday, July 25, 2025, and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 7878291 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, 

      7/22/25 8:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $BG
    $CAH
    $CNC
    $LOW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Centene Corporation

      SC 13G - CENTENE CORP (0001071739) (Subject)

      11/14/24 4:06:01 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/13/24 3:02:23 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/12/24 9:55:15 AM ET
      $CNC
      Medical Specialities
      Health Care